Idioma:

Female Recruitment Into Cardiovascular Disease Trials

Wu, Yingfei ; Prasanna, Anagha ; Miller, Hailey N. ; Ogungbe, Oluwabunmi ; Peeler, Anna ; Juraschek, Stephen P. ; Turkson-Ocran, Ruth-Alma ; Plante, Timothy B.

The American journal of cardiology, 2023-07, Vol.198, p.88-91 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Female Recruitment Into Cardiovascular Disease Trials
Autor: Wu, Yingfei ; Prasanna, Anagha ; Miller, Hailey N. ; Ogungbe, Oluwabunmi ; Peeler, Anna ; Juraschek, Stephen P. ; Turkson-Ocran, Ruth-Alma ; Plante, Timothy B.
Assuntos: Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - therapy ; Clinical trials ; Dependent variables ; Female ; Females ; Gender ; Gender aspects ; Gender identity ; Heart failure ; Humans ; Hyperlipidemia ; Hypertension ; Intervention ; Minority & ethnic groups ; Participation ; Patient Selection ; Recruitment ; Representations ; Systematic review ; Trends ; Variance analysis ; Women ; Womens health
É parte de: The American journal of cardiology, 2023-07, Vol.198, p.88-91
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Women are underrepresented in cardiovascular (CV) clinical trials, which may contribute to disease management and health equity barriers.1 Despite the National Institutes of Health (NIH) and the Food and Drug Administration policies recommending transparency and inclusion in reporting trial enrollment data by biologic gender, female representation in CV trials has not been adequately investigated. The participation to prevalence ratio (PPR) was obtained by dividing proportion of women in our sample's studies by the American Heart Association's estimated proportion in the corresponding US disease population.3 A PPR of 0.80 to 1.2 was considered adequate representation, <0.80 an underrepresentation, and >1.2 an overrepresentation.4 Independent-sample t tests with unequal variances or analysis of variance were used to test the statistical significance, with distribution of female participation as the dependent variable using Stata SE 16.1 (StataCorp, College Station, Texas). In this systematic review of NIH-funded CV disease trials, we found an underrepresentation of females, low prespecification of recruitment targets, low utilization of community-based and passive recruitment strategies, and no significant changes in recruitment trends throughout the past 2 decades. [...]this systematic review demonstrates a need for clearer delineation between biologic gender (e.g., female) and gender identity (e.g., women) in CV clinical trials.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Female Recruitment Into Cardiovascular Disease Trials

Wu, Yingfei ; Prasanna, Anagha ; Miller, Hailey N. ; Ogungbe, Oluwabunmi ; Peeler, Anna ; Juraschek, Stephen P. ; Turkson-Ocran, Ruth-Alma ; Plante, Timothy B.

United States: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.